•
Coronavirus: what can we do?
Talks about Coronavirus, Healthcare and Public Health
MA
Milad Alucozai
Founder of Wyss Institute at Harvard University
San Francisco, California
Overview
Milad Alucozai is a seasoned early-stage investor, biotech and healthcare executive, and serial entrepreneur based in San Francisco. He has a strong track record of co-founding successful ventures like Revalia Bio and Seqera Labs, as well as serving as a key board member for companies like Talus Bio and BoxOne Ventures.
Alucozai's career highlights include being recognized as Mentor of the Year by the Creative Destruction Lab and making impactful investments in companies like Eigen Therapeutics and Notable Labs, showcasing his expertise in identifying and supporting innovative startups in the biotech and healthcare sectors.
Work Experience
Co-Founder & Board Member
2024 - Current
We're developing AI-powered digital twins of living human organs by utilizing donated organs for research. These organs are revitalized using clinical-grade perfusion, generating a completely new source of data and transforming the landscape of biomedical research. This approach provides an unprecedented level of human data with direct clinical relevance.
Revalia Bio develops curative drugs for chronic organ-centered disease.
Raised $12,294,616.00 from National Kidney Foundation.
Co-Founder & Co-Host Code to Cure Series
2024
Code to Cure is a newsletter co-hosted by the Wyss Institute at Harvard University and Milad Alucozai on the intersection of AI, biology, and healthcare transforming medicine.
First investor and Board Member
2020
First investor and board member. Seqera is building the modern biotech stack by making scientific data analysis accessible at any scale. Seqera is the best solution for running robust, high-throughput computing at scale. From your first pipeline to running 10,000+ concurrent CPUs or workflows with >1,000,000 tasks, Seqera's architecture will grow with you - ensuring that computational bottlenecks never hinder scientific endeavors.
Strategic Expert in Residence
2024
Through Digitalis Commons, I am a Strategic Expert in Residence in support of the Advanced Research Projects Agency for Health (ARPA-H), where I support the US government and ARPA-H mission of enabling transformative biomedical and health breakthroughs to provide health solutions for all through non-dilutive investments. https://arpa-h.gov/
Member
2024
Established in 2009, C100 is a non-profit association with a mission to showcase exceptional leadership, harness extraordinary international talent, and fuel the pursuit of daring entrepreneurial ambitions in Canada.
Mentor - Recipient of Mentor of the Year Award
2019
Recipient of Mentor of the Year Award. Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. Its nine-month program allows founders to learn from experienced entrepreneurs, increasing their likelihood of success. The program has expanded to 12 sites across six countries. Participating ventures have created $28 billion (CAD) in equity value.
Board Member
2023
Talus Bio is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology.
Talus Bio is a drug discovery biotech company that develops drugs targeting undruggable transcription factors using AI.
Raised $27,781,502.00 from NFX, FundersClub, BoxOne Ventures, Two Bear Capital, Y Combinator Continuity Fund, Rolling Bay Ventures and WRF Capital.
Senior Advisor
2024 - 2025
16 Tech is a 50-acre innovation district in downtown Indianapolis dedicated to world-changing innovation and economic opportunity.
16 Tech is a 50-acre innovation district in downtown Indianapolis dedicated to world-changing innovation and economic opportunity.
Raised $40,000.00 from The Indianapolis Foundation.
Head of Life Sciences & Deep Tech
2018 - 2024
After nearly six incredible years, I have officially left BoxOne Ventures, filled with gratitude and excitement. My journey has been transformative, and I am immensely proud of what we have achieved together. In 2018, I met Josh at Creative Destruction Lab. We connected over our mutual passion for pushing the boundaries of bioengineering and computational advancement. We immediately began finding ways to work together and make investments, often as the first check into startups run by world-class founders. Fast forward nearly six years, we've built a firm recognized as one of the most active early-stage investors, with a portfolio exceeding 100 companies and multiple successful exits. Our brand stands as a testament to our founders and community partners who collaborate with us to make this possible.
Board Member
2022 - 2024
Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip.
Raised $31,000,000.00 from Reimagined Ventures, TDK Ventures, Section 32, Peak 6, Novartis, Sands Capital Ventures, Fiscus Ventures, Debiopharm Innovation Fund and Elementum Ventures.